GENEVAâ€”The recent success of treatment with immune checkpoint inhibitors suggests that immunotherapy could presently move center stage to play a leading role in fighting non-small cell lung cancerâ€”the European Lung Cancer Conference heard from Solange Peters, MD-PhD who leads the thoracic malignancies program in the Department of Oncology of the University of Lausanne. She discussed the new methods needed to harness these therapies and manage their toxicities with Oncology Times reporter Peter Goodwin.
You may also like...
Physical Therapy Survey Shows Clinical Practice Guideline Brought Benefit 19 Oct, 2017 Normal stem cells are not depleted in acute myeloid leukaemia and could be targeted therapeutically 9 Aug, 2013 Pelvic Radiotherapy Brought No Benefit in High-Risk Localized Prostate Cancer: GETUG 12 Trial 9 May, 2015 Breast Cancer Prognostic Implications of Obesity and Insulin Resistance 28 Mar, 2015
- Previous story Three Drug Regimen Best for Squamous Non Small Cell Lung Cancerâ€”Even in Older Patients
- Next story Combining Checkpoint Inhibition With Other Therapies for Lung Cancer
- COVID-19 Co-Morbidity Risks Quantified from Three Continents SurveyMay 28, 2020
- Ultrahypofractionated Radiation Just As Effective for Prostate CancerMay 16, 2018
- First evidence that genome editing made patients with AIDS more resistant to HIVMarch 8, 2014
- Anticoagulation with warfarin can be beneficial in patients with atrial fibrillation and chronic kidney disease.March 7, 2014
- Prostate cancer: Adult exposure to bisphenol-A linked to prostate cancer riskMarch 6, 2014